Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2 type I diabetic mice

Nasrallah R, Xiong H, Hébert RL. Renal prostaglandin E2 receptor (EP) expression profile is altered in streptozotocin and B6-Ins2 type I diabetic mice. Am J Physiol Renal Physiol 292: F278–F284, 2007. First published September 5, 2006; doi:10.1152/ajprenal.00089.2006.—The homeostatic function of prostaglandin E2 (PGE2) is dependent on a balance of EP receptormediated events. A disruption in this balance may contribute to the progression of renal injury. Although PGE2 excretion is elevated in diabetes, the expression of specific EP receptor subtypes has not been studied in the diabetic kidney. Therefore, the purpose of this study was to characterize the expression profile of four EP receptor subtypes (EP1-4) in 16-wk streptozotocin (STZ) and B6-Ins2 type I diabetic mice. In diabetic mice, the ratio of kidney weight to body weight was increased twofold compared with controls, blood glucose was elevated, but urine albumin was only increased in B6-Ins2 mice. The excretion of PGE2 and its metabolite was augmented twoto fourfold as determined by enzyme immunoassay. Accordingly, renal cyclooxygenases were also increased in diabetic mice, with isoform-specific and regional differences in each model. Finally, there was altered EP1-4 receptor expression in diabetic kidneys, with significant differences between STZ and B6-Ins2 mice (fold-control). In STZ mice, cortical EP1 increased by 1.6, EP3 increased by 2.3, and EP4 decreased by 0.63; yet in B6-Ins2 mice, cortical EP1 increased by 2.4, but there was a general decrease in the remaining subtypes. Similarly, in the STZ medulla EP3 increased by 3.6, but both EP1 and EP3 increased by 5.5 and 1.95, respectively, in B6-Ins2 mice. Therefore, knowing the pattern of change in relative EP receptor expression in the kidney could be useful in identifying specific EP targets for the prevention of various components of diabetic kidney disease.